{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:20:15Z","timestamp":1787239215882,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1501,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Medac GmbH"},{"name":"National Cancer Institute and National Heart Lung Blood Institute","award":["CA100394, HL036444, and HL088021"],"award-info":[{"award-number":["CA100394, HL036444, and HL088021"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.bbmt.2010.05.007","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T10:04:25Z","timestamp":1274954665000},"page":"341-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for\u00a0High-Risk Hematologic Malignancies"],"prefix":"10.1016","volume":"17","author":[{"given":"Eneida R.","family":"Nemecek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Guthrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine C.","family":"Doney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf A.","family":"Hilger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tibor J.","family":"Kovacsovics","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Woolfrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bedalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean E.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen J.","family":"Sickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Witherspoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2010.05.007_bib1","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2008-07-163212","article-title":"The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation","volume":"113","author":"Ringd\u00e9n","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(09)70352-3","article-title":"Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial","volume":"11","author":"Friedrichs","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/10428190903419130","article-title":"Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis","volume":"51","author":"Shi-Xia","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2010.05.007_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bbmt.2008.06.009","article-title":"Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide","volume":"14","author":"Bredeson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib5","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bmt.1703337","article-title":"Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia","volume":"29","author":"Balduzzi","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib7","series-title":"Thomas' Hematopoietic Cell Transplantation","first-page":"1043","article-title":"Reduced-intensity conditioning followed by hematopoietic cell transplantation for hematologic malignancies","author":"Sandmaier","year":"2009"},{"key":"10.1016\/j.bbmt.2010.05.007_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2003-11-3750","article-title":"Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.27.1460","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia","author":"Gyurkocza","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib10","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","article-title":"Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome","volume":"28","author":"McClune","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib11","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2004-03-0804","article-title":"Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA matched related donors","volume":"104","author":"Diaconescu","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib12","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1704062","article-title":"Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor","volume":"31","author":"Sayer","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloabltive, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1021\/jm00300a034","article-title":"Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate","volume":"13","author":"Feit","year":"1970","journal-title":"J Med Chem"},{"key":"10.1016\/j.bbmt.2010.05.007_bib16","first-page":"4209","article-title":"Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies","volume":"6","author":"Scheulen","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2010.05.007_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","article-title":"Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bmt.1705259","article-title":"Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)","volume":"37","author":"Kroger","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/ajh.21240","article-title":"Treosulfan\/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients","volume":"83","author":"Baronciani","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib20","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1365-2141.2008.07399.x","article-title":"Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation","volume":"143","author":"Cutting","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00277-007-0294-6","article-title":"Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation","volume":"86","author":"Blau","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/sj.bmt.1705605","article-title":"Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma","volume":"39","author":"Schmidt-Hieber","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.5414\/CPP42654","article-title":"Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Hilger","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.bbmt.2010.05.007_bib24","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2003.11.004","article-title":"Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model","volume":"10","author":"Ploemacher","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.exphem.2003.09.023","article-title":"Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1","volume":"32","author":"Schmidmaier","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0959-8049(02)00767-0","article-title":"Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL)","volume":"39","author":"Fichtner","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2010.05.007_bib27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00280-007-0669-3","article-title":"Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patients","volume":"62","author":"Munkelt","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib28","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2008"},{"key":"10.1016\/j.bbmt.2010.05.007_bib29","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib30","doi-asserted-by":"crossref","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","article-title":"Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group","volume":"103","author":"Bennett","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2010.05.007_bib31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","article-title":"A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties","volume":"107","author":"Wheatley","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib33","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","article-title":"Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)","volume":"109","author":"Schultz","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib35","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib36","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-10-116186","article-title":"Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group study SWOG-9400","volume":"111","author":"Pullarkat","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib37","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib38","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib39","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.bbmt.2009.11.017","article-title":"The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse nortality in acutel myelogenous leukemia","volume":"16","author":"Russell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib41","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/08923970902865683","article-title":"Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats","volume":"31","author":"Sender","year":"2009","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.bbmt.2010.05.007_bib42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bmt.1704784","article-title":"Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications","volume":"35","author":"Beelen","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib43","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells","volume":"102","author":"Bornhauser","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib45","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bbmt.2005.12.036","article-title":"Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan\/cyclophosphamide regimen","volume":"12","author":"Deeg","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.leu.2403591","article-title":"Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning","volume":"19","author":"Shimoni","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2010.05.007_bib47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib48","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib49","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1182\/blood-2009-03-213298","article-title":"Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"114","author":"Pagel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2010.05.007_bib50","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2010.05.007_bib51","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2009.03.007","article-title":"Transplant conditioning regimens: can we say it better?","volume":"15","author":"Deeg","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110002193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879110002193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:39:27Z","timestamp":1761057567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879110002193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S1083879110002193"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.05.007","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for\u00a0High-Risk Hematologic Malignancies","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2010.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}